Companies / Israel
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Teva Showcases Novel Drug Pipeline
September 2006 | Project NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
In an attempt to draw attention away from its successful but stable generic business, Israeli firm Teva Pharmaceutical Industries has showcased its pipeline of branded pharmaceuticals. Teva is planning to make 15 regulatory submissions between 2009-2015, which is a considerable task for a firm that only has two branded pharmaceutical products and a pipeline that could be described as modest at best and containing decidedly high-risk candidates, according to